The Serological Sciences Network (SeroNet) for COVID-19 : Depth and Breadth of Serology Assays and Plans for Assay Harmonization
In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and "to develop, validate, improve, and implement serological testing and associated technologies" (https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-initiatives/serological-sciences-network). SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization. To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology standard reference material and first WHO international standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data. SeroNet institutions reported development of a total of 27 enzyme-linked immunosorbent assay (ELISA) methods, 13 multiplex assays, and 9 neutralization assays and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards. In conclusion, SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons. IMPORTANCE SeroNet institutions have developed or implemented 61 diverse COVID-19 serological assays and are collaboratively working to harmonize these assays using reference materials to establish standardized reporting units. This will facilitate clinical interpretation of serology results and cross-comparison of research data.
| Errataetall: | |
|---|---|
| Medienart: |
E-Artikel |
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:7 |
|---|---|
| Enthalten in: |
mSphere - 7(2022), 4 vom: 31. Aug., Seite e0019322 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Themen: |
Antibodies, Viral |
|---|
| Anmerkungen: |
Date Completed 08.09.2022 Date Revised 20.09.2022 published: Print-Electronic UpdateOf: medRxiv. 2022 Mar 14;:. - PMID 35262095 Citation Status MEDLINE |
|---|
| doi: |
10.1128/msphere.00193-22 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM34225006X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM34225006X | ||
| 003 | DE-627 | ||
| 005 | 20231226013654.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1128/msphere.00193-22 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1140.xml |
| 035 | |a (DE-627)NLM34225006X | ||
| 035 | |a (NLM)35703544 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Karger, Amy B |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The Serological Sciences Network (SeroNet) for COVID-19 |b Depth and Breadth of Serology Assays and Plans for Assay Harmonization |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.09.2022 | ||
| 500 | |a Date Revised 20.09.2022 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a UpdateOf: medRxiv. 2022 Mar 14;:. - PMID 35262095 | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a In October 2020, the National Cancer Institute (NCI) Serological Sciences Network (SeroNet) was established to study the immune response to COVID-19, and "to develop, validate, improve, and implement serological testing and associated technologies" (https://www.cancer.gov/research/key-initiatives/covid-19/coronavirus-research-initiatives/serological-sciences-network). SeroNet is comprised of 25 participating research institutions partnering with the Frederick National Laboratory for Cancer Research (FNLCR) and the SeroNet Coordinating Center. Since its inception, SeroNet has supported collaborative development and sharing of COVID-19 serological assay procedures and has set forth plans for assay harmonization. To facilitate collaboration and procedure sharing, a detailed survey was sent to collate comprehensive assay details and performance metrics on COVID-19 serological assays within SeroNet. In addition, FNLCR established a protocol to calibrate SeroNet serological assays to reference standards, such as the U.S. severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) serology standard reference material and first WHO international standard (IS) for anti-SARS-CoV-2 immunoglobulin (20/136), to facilitate harmonization of assay reporting units and cross-comparison of study data. SeroNet institutions reported development of a total of 27 enzyme-linked immunosorbent assay (ELISA) methods, 13 multiplex assays, and 9 neutralization assays and use of 12 different commercial serological methods. FNLCR developed a standardized protocol for SeroNet institutions to calibrate these diverse serological assays to reference standards. In conclusion, SeroNet institutions have established a diverse array of COVID-19 serological assays to study the immune response to SARS-CoV-2 and vaccines. Calibration of SeroNet serological assays to harmonize results reporting will facilitate future pooled data analyses and study cross-comparisons. IMPORTANCE SeroNet institutions have developed or implemented 61 diverse COVID-19 serological assays and are collaboratively working to harmonize these assays using reference materials to establish standardized reporting units. This will facilitate clinical interpretation of serology results and cross-comparison of research data | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SeroNet | |
| 650 | 4 | |a assay harmonization | |
| 650 | 4 | |a serology | |
| 650 | 7 | |a Antibodies, Viral |2 NLM | |
| 700 | 1 | |a Brien, James D |e verfasserin |4 aut | |
| 700 | 1 | |a Christen, Jayne M |e verfasserin |4 aut | |
| 700 | 1 | |a Dhakal, Santosh |e verfasserin |4 aut | |
| 700 | 1 | |a Kemp, Troy J |e verfasserin |4 aut | |
| 700 | 1 | |a Klein, Sabra L |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Ligia A |e verfasserin |4 aut | |
| 700 | 1 | |a Premkumar, Lakshmanane |e verfasserin |4 aut | |
| 700 | 1 | |a Roback, John D |e verfasserin |4 aut | |
| 700 | 1 | |a Binder, Raquel A |e verfasserin |4 aut | |
| 700 | 1 | |a Boehme, Karl W |e verfasserin |4 aut | |
| 700 | 1 | |a Boppana, Suresh |e verfasserin |4 aut | |
| 700 | 1 | |a Cordon-Cardo, Carlos |e verfasserin |4 aut | |
| 700 | 1 | |a Crawford, James M |e verfasserin |4 aut | |
| 700 | 1 | |a Daiss, John L |e verfasserin |4 aut | |
| 700 | 1 | |a Dupuis, Alan P |c 2nd |e verfasserin |4 aut | |
| 700 | 1 | |a Espino, Ana M |e verfasserin |4 aut | |
| 700 | 1 | |a Firpo-Betancourt, Adolfo |e verfasserin |4 aut | |
| 700 | 1 | |a Forconi, Catherine |e verfasserin |4 aut | |
| 700 | 1 | |a Forrest, J Craig |e verfasserin |4 aut | |
| 700 | 1 | |a Girardin, Roxie C |e verfasserin |4 aut | |
| 700 | 1 | |a Granger, Douglas A |e verfasserin |4 aut | |
| 700 | 1 | |a Granger, Steve W |e verfasserin |4 aut | |
| 700 | 1 | |a Haddad, Natalie S |e verfasserin |4 aut | |
| 700 | 1 | |a Heaney, Christopher D |e verfasserin |4 aut | |
| 700 | 1 | |a Hunt, Danielle T |e verfasserin |4 aut | |
| 700 | 1 | |a Kennedy, Joshua L |e verfasserin |4 aut | |
| 700 | 1 | |a King, Christopher L |e verfasserin |4 aut | |
| 700 | 1 | |a Krammer, Florian |e verfasserin |4 aut | |
| 700 | 1 | |a Kruczynski, Kate |e verfasserin |4 aut | |
| 700 | 1 | |a LaBaer, Joshua |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, F Eun-Hyung |e verfasserin |4 aut | |
| 700 | 1 | |a Lee, William T |e verfasserin |4 aut | |
| 700 | 1 | |a Liu, Shan-Lu |e verfasserin |4 aut | |
| 700 | 1 | |a Lozanski, Gerard |e verfasserin |4 aut | |
| 700 | 1 | |a Lucas, Todd |e verfasserin |4 aut | |
| 700 | 1 | |a Mendu, Damodara Rao |e verfasserin |4 aut | |
| 700 | 1 | |a Moormann, Ann M |e verfasserin |4 aut | |
| 700 | 1 | |a Murugan, Vel |e verfasserin |4 aut | |
| 700 | 1 | |a Okoye, Nkemakonam C |e verfasserin |4 aut | |
| 700 | 1 | |a Pantoja, Petraleigh |e verfasserin |4 aut | |
| 700 | 1 | |a Payne, Anne F |e verfasserin |4 aut | |
| 700 | 1 | |a Park, Jin |e verfasserin |4 aut | |
| 700 | 1 | |a Pinninti, Swetha |e verfasserin |4 aut | |
| 700 | 1 | |a Pinto, Amelia K |e verfasserin |4 aut | |
| 700 | 1 | |a Pisanic, Nora |e verfasserin |4 aut | |
| 700 | 1 | |a Qiu, Ji |e verfasserin |4 aut | |
| 700 | 1 | |a Sariol, Carlos A |e verfasserin |4 aut | |
| 700 | 1 | |a Simon, Viviana |e verfasserin |4 aut | |
| 700 | 1 | |a Song, Lusheng |e verfasserin |4 aut | |
| 700 | 1 | |a Steffen, Tara L |e verfasserin |4 aut | |
| 700 | 1 | |a Stone, E Taylor |e verfasserin |4 aut | |
| 700 | 1 | |a Styer, Linda M |e verfasserin |4 aut | |
| 700 | 1 | |a Suthar, Mehul S |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Stefani N |e verfasserin |4 aut | |
| 700 | 1 | |a Thyagarajan, Bharat |e verfasserin |4 aut | |
| 700 | 1 | |a Wajnberg, Ania |e verfasserin |4 aut | |
| 700 | 1 | |a Yates, Jennifer L |e verfasserin |4 aut | |
| 700 | 1 | |a Sobhani, Kimia |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t mSphere |d 2016 |g 7(2022), 4 vom: 31. Aug., Seite e0019322 |w (DE-627)NLM259701831 |x 2379-5042 |7 nnns |
| 773 | 1 | 8 | |g volume:7 |g year:2022 |g number:4 |g day:31 |g month:08 |g pages:e0019322 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1128/msphere.00193-22 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 7 |j 2022 |e 4 |b 31 |c 08 |h e0019322 | ||